Geneva, Switzerland, January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neur ...
Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand 13 patients have completed full 48-week treatment in DKD trial; no safety signals identified Phase 2 IPF trial funded by NIH; poised to init ...
Collaboration follows data from ANGEL-MS extension to Phase 2 MS trial Aims to address key unmet need of slowing or stopping disease progression Geneva, Switzerland, November 25, 2019 – 7:30am CET ...
A must-attend and rapidly growing event with experts around the world: 36 speakers from 10 countries In-depth scientific review of the role played by the HERVs in a broad range of diseases including multiple scl ...
Further evidence adds to already strong set of positive clinical data Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Pari ...
Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of nonnormal distribution (outliers) in 400mg OD In advanced patients, setanax ...
